Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus MECAMYLAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus MECAMYLAMINE HYDROCHLORIDE.
CONSENSI vs MECAMYLAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Category C
Category C
Antihypertensive/NSAID Combination
Antihypertensive